- Diseases
- Acoustic Neuroma (14)
- Adrenal Gland Tumor (24)
- Anal Cancer (66)
- Anemia (2)
- Appendix Cancer (16)
- Bile Duct Cancer (28)
- Bladder Cancer (68)
- Brain Metastases (28)
- Brain Tumor (228)
- Breast Cancer (716)
- Breast Implant-Associated Anaplastic Large Cell Lymphoma (2)
- Cancer of Unknown Primary (4)
- Carcinoid Tumor (8)
- Cervical Cancer (154)
- Colon Cancer (164)
- Colorectal Cancer (110)
- Endocrine Tumor (4)
- Esophageal Cancer (42)
- Eye Cancer (36)
- Fallopian Tube Cancer (6)
- Germ Cell Tumor (4)
- Gestational Trophoblastic Disease (2)
- Head and Neck Cancer (6)
- Kidney Cancer (124)
- Leukemia (344)
- Liver Cancer (50)
- Lung Cancer (288)
- Lymphoma (284)
- Mesothelioma (14)
- Metastasis (30)
- Multiple Myeloma (98)
- Myelodysplastic Syndrome (60)
- Myeloproliferative Neoplasm (4)
- Neuroendocrine Tumors (16)
- Oral Cancer (100)
- Ovarian Cancer (170)
- Pancreatic Cancer (166)
- Parathyroid Disease (2)
- Penile Cancer (14)
- Pituitary Tumor (6)
- Prostate Cancer (144)
- Rectal Cancer (58)
- Renal Medullary Carcinoma (6)
- Salivary Gland Cancer (14)
- Sarcoma (236)
- Skin Cancer (294)
- Skull Base Tumors (56)
- Spinal Tumor (12)
- Stomach Cancer (60)
- Testicular Cancer (28)
- Throat Cancer (90)
- Thymoma (6)
- Thyroid Cancer (98)
- Tonsil Cancer (30)
- Uterine Cancer (78)
- Vaginal Cancer (14)
- Vulvar Cancer (18)
- Cancer Topic
- Adolescent and Young Adult Cancer Issues (20)
- Advance Care Planning (10)
- Biostatistics (2)
- Blood Donation (18)
- Bone Health (8)
- COVID-19 (362)
- Cancer Recurrence (120)
- Childhood Cancer Issues (120)
- Clinical Trials (624)
- Complementary Integrative Medicine (24)
- Cytogenetics (2)
- DNA Methylation (4)
- Diagnosis (228)
- Epigenetics (6)
- Fertility (62)
- Follow-up Guidelines (2)
- Health Disparities (14)
- Hereditary Cancer Syndromes (122)
- Immunology (18)
- Li-Fraumeni Syndrome (8)
- Mental Health (118)
- Molecular Diagnostics (8)
- Pain Management (62)
- Palliative Care (8)
- Pathology (10)
- Physical Therapy (18)
- Pregnancy (18)
- Prevention (890)
- Research (390)
- Second Opinion (74)
- Sexuality (16)
- Side Effects (602)
- Sleep Disorders (10)
- Stem Cell Transplantation Cellular Therapy (216)
- Support (404)
- Survivorship (322)
- Symptoms (184)
- Treatment (1770)
Targeted drug melts fat, weight and waistlines in obese monkeys
2 minute read | Published November 09, 2011
Medically Reviewed | Last reviewed by an MD Anderson Cancer Center medical professional on November 09, 2011
An experimental drug that directly reduces fat by destroying the blood vessels that support it caused an 11 percent weight loss in obese rhesus monkeys in a month's time.
"Development of this compound for human use would provide a non-surgical way to actually reduce accumulated white fat, in contrast to current weight-loss drugs that attempt to control appetite or prevent absorption of dietary fat," says Renata Pasqualini, Ph.D., professor in MD Anderson's David H. Koch Center for Applied Research of Genitourinary Cancers.
"We're greatly encouraged to see substantial weight loss in a primate model of obesity that closely matches the human condition," Pasqualini says.
Treated monkeys had corresponding reductions in waist circumference and body mass index. Untreated control monkeys were largely unchanged during the study.
Imaging studies showed treated monkeys lost 38% of their body fat, including 27% of their abdominal fat, indicating that weight loss was caused by fat reduction and not the loss of other types of tissue.
At the start of the study, none of the monkeys were diabetic, but they did have heightened insulin resistance, which raises risk of developing type 2 diabetes and cardiovascular disease. Treated monkeys showed marked improvements in insulin resistance - using about 50 percent less insulin after treatment.
Lean monkeys in a dosing study did not lose weight when treated with the drug.
"Obesity is a major risk factor for developing cancer, roughly the equivalent of tobacco use, and both are potentially reversible" says Wadih Arap, M.D., Ph.D., also professor in the Koch Center. "Obese cancer patients do worse in surgery, with radiation or on chemotherapy - worse by any measure."
Arap, Pasqualini and colleagues are developing a clinical trial of the drug for obese prostate cancer patients to submit to the U.S. Food and Drug Administration for approval.
The scientists published their findings in Science Translational Medicine.
Additional resources MD Anderson news release Science Translational Medicine paper